Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke.

PloS one - 1 Jan 2011

Tomasi Simone, Sarmientos Paolo, Giorda Giada, Gurewich Victor, Vercelli Alessandro

Abstract excerpt

A single-site mutant (M5) of native urokinase plasminogen activator (prouPA) induces effective thrombolysis in dogs with venous or arterial thrombosis with a reduction in bleeding complications compared to tPA. This effect, related to inhibition of two-chain M5 (tcM5) by plasma C1-inhibitor (C1I), thereby preventing non-specific plasmin generation, was augmented by the addition of exogenous C1I to plasma in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement C1 Inhibitor Protein
Share to Dogs
Share to Guinea Pigs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Rabbits

Share to Rats, Sprague-Dawley

Share to Recombinant Proteins

Share to Stroke

Share to Urokinase-Type Plasminogen Activator

Source

Open in PubMed Open full text

Identifiers

PMID: 21779364
DOI: 10.1371/journal.pone.0021999
PMCID: PMC3136496

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke.PMID 21779364Read ↗

Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.Semantic proximity Read ↗

Blood-brain barrier permeability and tPA-mediated neurotoxicity.Semantic proximity Read ↗

Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.Semantic proximity Read ↗

S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.Semantic proximity Read ↗

Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice.Semantic proximity Read ↗

Newer thrombolytic agents.Semantic proximity Read ↗

A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenolSemantic proximity Read ↗

Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.Semantic proximity Read ↗

Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins.Semantic proximity Read ↗

Impact of Age and ASPECTS 0-5 on Mechanical Thrombectomy Outcomes: Analysis from the STRATIS RegistrySemantic proximity Read ↗

Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.Semantic proximity Read ↗

The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.